Risk of subsequent primary leukaemias among 69,460 five-year survivors of childhood cancer diagnosed from 1940 to 2008 in Europe: A cohort study within PanCareSurFup

Allodji, Rodrigue S.; Hawkins, Mike; Bright, Chloe J; Fidler-Benaoudia, Miranda M; Winter, D.; Alessi, Daniela; Fresneau, Brice; Journy, Neige; Morsellino, Vera; Bárdi, Edit; Bautz, Andrea; Byrne, Julianne; Feijen, Elizabeth Lieke; Teepen, Jop C.; Vu‐Bezin, Giao; Rubino, Carole; Garwicz, Stanislaw; Grabow, Desiree; Guðmundsdóttir, Þorgerður; Guha, Joyeeta; Hau, Eva-Maria; Jankovic, Momcilo; Kaatsch, Peter; Kaiser, Melanie; Linge, Helena M.; Muraca, Monica; Llanas, Damien; Veres, Cristina; Øfstaas, Hilde; Diallo, Ibrahima; Mansouri, Imène; Ronckers, Cécile M.; Skinner, Roderick; Terenziani, Monica; Wesenberg, Finn; Wiebe, Thomas; Sacerdote, Carlotta; Jakab, Zsuzsanna; Haupt, Riccardo; Lähteenmäki, Päivi; Zadravec-Zaletel, Lorna; Kuehni, Claudia E.; Winther, Jeanette Falck; Michel, Gisela; Kremer, Leontien C. M.; Hjorth, Lars; Haddy, Nadia; Vathaire, Florent de; Reulen, Raoul C.

doi:10.1016/j.ejca.2019.05.013

Cited by 15 publications

(17 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because of improving survival and lack of preventive measures to preclude the disease (2,11), the number of childhood cancer survivors reaching adulthood is steadily increasing. This growing population, with many years of life ahead of them, has increased attention and concerns about the risk of late effects induced by cancer treatment exposures at a young age (12) and attracted great interest towards survivorship research (13)(14)(15). Survivors of childhood cancer are at risk for various somatic and mental health conditions attributable to the cancer and its treatment (4,5) as well as adverse social and socioeconomic consequences and diminished psychological well-being and quality of life (16)(17)(18)(19).…”

Section: Introductionmentioning

confidence: 99%

Childhood cancer: Survival, treatment modalities, late effects and improvements over time

Erdmann

Frederiksen

Bonaventure

et al. 2021

Cancer Epidemiology

183

144

View full text Add to dashboard Cite

Highlights Improvements in childhood cancer survival led to increasing numbers of survivors  Childhood cancer is treated within multiinstitutional clinical trials  Chemotherapy is the main element of therapy but irradiation is still needed in some  Survivors are at longstanding risk of severe somatic late effects  Survivors may face various social and socioeconomic difficulties in adulthood

show abstract

Section: Introductionmentioning

confidence: 99%

Childhood cancer: Survival, treatment modalities, late effects and improvements over time

Erdmann

Frederiksen

Bonaventure

et al. 2021

Cancer Epidemiology

183

144

View full text Add to dashboard Cite

show abstract

“…The late toxicity of current cancer treatments is linked to the higher incidence of primary cancers, including sarcoma or leukemia, later in life. A group of patients especially vulnerable to treatment-induced secondary malignancies are childhood cancer survivors [ 120 , 121 ]. Taking the above into account, there is a need for the establishment of less toxic and affordable treatments.…”

Section: Targeting P53 Protein Family For Improved Cancer Therapy mentioning

confidence: 99%

The Undervalued Avenue to Reinstate Tumor Suppressor Functionality of the p53 Protein Family for Improved Cancer Therapy-Drug Repurposing

Zawacka-Pankau

2020

Cancers

View full text Add to dashboard Cite

p53 and p73 are critical tumor suppressors that are often inactivated in human cancers through various mechanisms. Owing to their high structural homology, the proteins have many joined functions and recognize the same set of genes involved in apoptosis and cell cycle regulation. p53 is known as the ‘guardian of the genome’ and together with p73 forms a barrier against cancer development and progression. The TP53 is mutated in more than 50% of all human cancers and the germline mutations in TP53 predispose to the early onset of multiple tumors in Li–Fraumeni syndrome (LFS), the inherited cancer predisposition. In cancers where TP53 gene is intact, p53 is degraded. Despite the ongoing efforts, the treatment of cancers remains challenging. This is due to late diagnoses, the toxicity of the current standard of care and marginal benefit of newly approved therapies. Presently, the endeavors focus on reactivating p53 exclusively, neglecting the potential of the restoration of p73 protein for cancer eradication. Taken that several small molecules reactivating p53 failed in clinical trials, there is a need to develop new treatments targeting p53 proteins in cancer. This review outlines the most advanced strategies to reactivate p53 and p73 and describes drug repurposing approaches for the efficient reinstatement of the p53 proteins for cancer therapy.

show abstract

“…The late toxicity of current cancer treatments is linked to higher incidence of primary cancers including sarcoma or leukemia later in life. A group of patients especially vulnerable to secondary malignancies are childhood cancer survivors [121,122]. Taken the above, there is a need for the establishment of less toxic and affordable treatments.…”

Section: Drug Repurposingmentioning

confidence: 99%

The Undervalued Avenue to Reinstate Tumor Suppressor Functionality of the p53 Protein Family for Improved Cancer Therapy - Drug Repurposing

Zawacka-Pankau

2020

Preprint

View full text Add to dashboard Cite

p53 and p73 are critical tumor suppressors often inactivated in human cancers through various mechanisms. Owing to high structural homology, the proteins have many common functions and recognize the same set of genes involved in apoptosis and cell cycle regulation. p53 is known as the ‘guardian of the genome’ and together with p73 form a barrier against cancer development and progression. The TP53 is mutated in more than 50% of all human cancers and the germline mutations in TP53 predispose to the early onset of multiple tumors in Li-Fraumeni Syndrome (LFS), the inherited cancer predisposition. In cancers where TP53 gene is intact, p53 is degraded. Despite the ongoing efforts, the treatment of cancers remains challenging. This is due to late diagnoses, the toxicity of current standard of care and marginal benefit of newly approved therapies. Presently, the endeavours focus on reactivating p53 exclusively, neglecting the potential of the restoration of p73 protein for cancer eradication. Taken that several small molecules reactivating p53 failed in clinical trials, there is a need to develop new treatments targeting p53 proteins in cancer. This review outlines the most advanced strategies to reactivate p53 and p73 and describes drug repurposing approaches for the efficient reinstatement of the p53 proteins for cancer therapy.

show abstract

Risk of subsequent primary leukaemias among 69,460 five-year survivors of childhood cancer diagnosed from 1940 to 2008 in Europe: A cohort study within PanCareSurFup

Cited by 15 publications

References 26 publications

Childhood cancer: Survival, treatment modalities, late effects and improvements over time

Childhood cancer: Survival, treatment modalities, late effects and improvements over time

The Undervalued Avenue to Reinstate Tumor Suppressor Functionality of the p53 Protein Family for Improved Cancer Therapy-Drug Repurposing

The Undervalued Avenue to Reinstate Tumor Suppressor Functionality of the p53 Protein Family for Improved Cancer Therapy - Drug Repurposing

Contact Info

Product

Resources

About